<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044325</url>
  </required_header>
  <id_info>
    <org_study_id>213376</org_study_id>
    <nct_id>NCT05044325</nct_id>
  </id_info>
  <brief_title>A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants</brief_title>
  <official_title>A Two-Part First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Oral Doses of GSK3884464 in a Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a FTIH study which aims to evaluate safety, tolerability, pharmacokinetics (PK)&#xD;
      and pharmacodynamics (PD) of single and repeat oral doses of GSK3884464 administered to&#xD;
      healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">October 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of participants with adverse events (AEs)</measure>
    <time_frame>Day 1 through Week 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with clinically significant changes in laboratory values, vital signs and 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Up to Week 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with clinically significant changes in continuous telemetry</measure>
    <time_frame>Day 1 through Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Number of participants with clinically significant changes in laboratory values, vital signs, 12-lead ECG and echocardiogram</measure>
    <time_frame>Day 1 through Week 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: Number of participants with clinically significant changes in laboratory values, vital signs, 12-lead ECG and echocardiogram</measure>
    <time_frame>Day 1 through Week 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Number of participants with clinically significant changes in continuous telemetry</measure>
    <time_frame>Day 1 through Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: Number of participants with clinically significant changes in continuous telemetry</measure>
    <time_frame>Day 1 through Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area under the plasma concentration curve from time zero to last time of quantifiable concentration (AUC[0-t]) of GSK3884464 following single dose administration</measure>
    <time_frame>Day 1 pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUC from time zero to infinity (AUC[0-inf]) of GSK3884464 following single dose administration</measure>
    <time_frame>Day 1 pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum observed plasma concentration (Cmax) of GSK3884464 following single dose administration</measure>
    <time_frame>Day 1 pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time to maximum observed plasma drug concentration (Tmax) of GSK3884464 following single dose administration</measure>
    <time_frame>Day 1 pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Terminal half-life (T1/2) of GSK3884464 following single dose administration</measure>
    <time_frame>Day 1 pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: AUC over the dosing interval (AUC[tau]) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: AUC(tau) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Cmax of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: Cmax of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Trough plasma concentration (Ctau) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: Ctau of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Tmax of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: Tmax of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: T1/2 of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: T1/2 of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Accumulation ratio based on AUC(tau) (RAUC) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: RAUC of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Accumulation ratio based on Cmax (RCmax) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: RCmax of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Accumulation ratio based on Ctau (RCtau) of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4 and Day 11: pre-dose; Day 7: pre-dose, 6 and 12 hours post-dose; Day 14: pre-dose, 30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cohort 6: RCtau of GSK3884464 following repeat dose administration</measure>
    <time_frame>Day 1:pre-dose,30 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours post-dose; Day 4, Day 11 and Day 18:pre-dose; Day 7:pre-dose,6 and 12 hours post-dose; Day 21:pre-dose, 30 minutes,1, 1.5, 2, 3, 4, 6, 8, 12, 18,24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from Baseline in NAD(P)H dehydrogenase Quinone 1 (NQO1) messenger Ribonucleic acid (mRNA) in whole blood post treatment with GSK3884464</measure>
    <time_frame>Baseline (Day 1) pre-dose, 2, 6, 12 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cohorts 4 and 5: Change from Baseline in NQO1 mRNA in whole blood post treatment with GSK3884464</measure>
    <time_frame>Baseline (Day 1), Days 7 and 14: pre-dose, 6 and 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cohort 6: Change from Baseline in NQO1 mRNA in whole blood post treatment with GSK3884464.</measure>
    <time_frame>Baseline (Day 1), Days 7 and 21: pre-dose, 6 and 12 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 1) + Placebo; in period 2: GSK3884464 (Dose 2) + Placebo and in period 3: GSK3884464 (Dose 3) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 4) + Placebo; in period 2: GSK3884464 (Dose 5) + Placebo and in period 3: GSK3884464 (Dose 6) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 7) + Placebo; in period 2: GSK3884464 (Dose 8) + Placebo and in period 3: GSK3884464 (Dose 9) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive either GSK3884464 (Dose X) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive either GSK3884464 (Dose Y) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive either GSK3884464 (Dose Z) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3884464</intervention_name>
    <description>GSK3884464 will be administered</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match GSK3884464 will be administered.</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy as determined by the experienced investigator or medically qualified designee&#xD;
             based on a medical evaluation including medical history, physical examination,&#xD;
             laboratory tests, and cardiac monitoring/assessment.&#xD;
&#xD;
          -  Part 1: Body weight greater than or equal to (&gt;=)50 kilograms (kg), body mass index&#xD;
             (BMI) &gt;=18 and less than or equal to (&lt;=)30 kilograms per square meter (kg/m^2)&#xD;
             (inclusive). Part 2: Body weight &gt;=50 kg, BMI &gt;=22 and &lt;=30 kg/m^2 (inclusive).&#xD;
&#xD;
          -  Participants with 18 to 50 years of age inclusive at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Male or females of non-childbearing potential.&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form and in this protocol.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal (Gastroesophageal reflux disease [GERD], nausea, vomiting or&#xD;
             dysphagia), endocrine, hematological or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study treatment; or interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  History of current or past significant renal diseases.&#xD;
&#xD;
          -  Clinically significant high blood pressure and/or history of hypertension as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or&#xD;
             squamous epithelial carcinomas of the skin that have been resected with no evidence of&#xD;
             metastatic disease for 3 years.&#xD;
&#xD;
          -  Breast cancer within the past 10 years.&#xD;
&#xD;
          -  Any clinically relevant abnormality on the screening medical assessments.&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drug.&#xD;
&#xD;
          -  A positive laboratory confirmation of Coronavirus Disease-2019 (COVID-19) infection,&#xD;
             or high clinical index of suspicion for COVID-19.&#xD;
&#xD;
          -  Participants with Glycated hemoglobin (HbA1c) greater than (&gt;)48 millimoles per mol&#xD;
             (mmol/mol) at screening.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen at screening.&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening.&#xD;
&#xD;
          -  Positive Hepatitis C RNA test result at screening or within 3 months prior to first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Positive Human immunodeficiency virus (HIV) antibody test.&#xD;
&#xD;
          -  Screening urine albumin to creatinine ratio &gt;30 milligrams/grams (mg/gm) (&gt;3 mg/mmol).&#xD;
&#xD;
          -  Regular use of known drugs of abuse.&#xD;
&#xD;
          -  Regular alcohol consumption within six months prior to the study defined as: An&#xD;
             average weekly intake of &gt;=14 units for males &gt;=14 units for females. One unit is&#xD;
             equivalent to 8 gm of alcohol: a half-pint (approximately 240 milliliters [mL]) of&#xD;
             beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  Smokelyzer test levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products (for example [e.g.] nicotine patches or vaporizing&#xD;
             devices) within 3 months prior to screening.&#xD;
&#xD;
          -  Participants with a history or current evidence of depression, bipolar disorder,&#xD;
             suicidal ideation and behavior, or a lifetime history of suicide attempt will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michalis S Kostapanos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Time in Human (FTIH)</keyword>
  <keyword>GSK3884464</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

